A convincing hit puts approval, and potentially partnerships, on the table.
But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
But large gains for some big pharma players flatter the overall figures.
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.